Vringo receives six-month delisting reprieve

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Vringo receives six-month delisting reprieve

The patent assertion entity announced today that it has received a six-month grace period to raise its share price to the $1 minimum

The US-based PAE has been involved in several high profile lawsuits, including a string of cases involving standards essential patents against Chinese telecommunications company ZTE around the world (venues include the UK, Germany, India, Romania and Brazil).

In 2012, Vringo won a $30 million judgment against Google after a district court found that the search engine’s AdWords and AdSense programs infringed patents Vringo acquired from Lycos. Last year, the Federal Circuit overturned the verdict, causing Vringo’s stock price to tumble from $3.15 to $0.88 per share. The price then hovered around $1, the minimum required to be listed on the NASDAQ, but since December 1 has been trading for less than that.

As of writing, VRNG is trading at slightly above 60 cents a share.

Vringo’s announcement comes at a time when there is some concern about the viability of the PAE business model. A study from RPX showed that 2014 saw a significant drop in NPE-initiated litigation activity, and there was a decrease in patent litigation overall. This year however has seen a rebound in the number in the number of patent cases filed. And recently, Ray Niro, considered by some to be one of the first patent rolls, said that the Supreme Court decision in Octane Fitness has increased the risk to plaintiffs may lead to him leaving the NPE business.

more from across site and SHARED ros bottom lb

More from across our site

Examiner statistics could help patent prosecution practitioners tailor strategies, turning an area of high variability into a potential competitive advantage
The England and Wales High Court’s ruling in Accord v Novartis may not rewrite the law on plausibility, but it does signal a pragmatic approach that could provide greater certainty for life sciences innovators
Firms with established sports relationships and specialised expertise are well positioned to capture the market’s expanded pool of IP work
Gunjan Paharia discusses developing RIA, an AI platform built to draw on decades of institutional knowledge, support junior lawyers, and reshape how legal teams work
A strong Canadian business helped lift profits, but the IP service group's latest results underline the pressure facing its operations in Australia, New Zealand and parts of Asia
Wins in court have been key to the six-year-old firm’s growth, as one of its founders explains
The firm’s co-CEO discusses patent litigation, collaboration with overseas colleagues and the next generation of leaders
Two recent decisions demonstrate the courts’ creativity in cutting-edge IP disputes that tested their jurisdictional powers
Aditi Verma Thakur, managing partner at Aishani Partners, discusses 5 am wake-ups, working with high-performing professionals and staying calm under pressure
After more than three decades at Wilson Sonsini, Ian Edvalson explains why he moved to expand his life sciences transactional practice
Gift this article